Quinolino[3,4-b]quinoxalines and pyridazino[4,3-c]quinoline derivatives: Synthesis, inhibition of topoisomerase IIα, G-quadruplex binding and cytotoxic properties

European Journal of Medicinal Chemistry

Volumn 123, Issue , 2016, Pages 704-717

  Palluotto, Fausta ^a   Sosic, Alice ^b   Pinato, Odra ^b   Zoidis, Grigoris ^c   Catto, Marco ^a   Sissi, Claudia ^b   Gatto, Barbara ^b   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cytotoxic agents; G quadruplex stabilizers; Pyridazine derivatives; Quinoline derivatives; Topoisomerase II inhibitors

Indexed keywords

3 HYDROXY 3 (2 OXOPROPYL)QUINOLINE 2,4(1H,3H) DIONE; 3 METHYLPYRIDAZINO[4,3-C]QUINOLIN 5(6H) ONE; 5 (2 (DIETHYLAMINO)ETHYL)QUINOLINO[3,4-B]QUINOXALIN 6(5H) ONE; 5 (2 (DIMETHYLAMINO)ETHYL)QUINOLINO[3,4-B]QUINOXALIN 6(5H) ONE; 5 (2 (MORPHOLINOETHYL)ETHYL)QUINOLINO[3,4-B]QUINOXALIN 6(5H) ONE; 5 (3 (DIMETHYLAMINO)PROPYL)QUINOLINO[3,4-B]QUINOXALIN 6(5H) ONE; 5 (4 (DIMETHYLAMINO)BUTYL)QUINOLINO [3,4-B]QUINOXALIN 6(5H) ONE; 5 (4 CHLOROBUTYL)QUINOLINO[3,4-B] QUINOXALIN 6(5H) ONE; 6 (2 (DIMETHYLAMINO)ETHYL) 3 METHYLPYRIDAZINO[4,3-C]QUINOLIN 5(6H) ONE; 6 (2 MORPHOLINOETHOXY)QUINOLINO[3,4-B]QUINOXALINE; 6 CHLOROQUINOLINO[3,4-B]QUINOXALINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GUANINE QUADRUPLEX; N (2 (DIETHYLAMINO)ETHYL)QUINOLINO[3,4-B]QUINOXALIN 6 AMINE; N (2 (DIETHYLAMINO)PROPYL)QUINOLINO[3,4-B]QUINOXALIN 6 AMINE; N (2 (DIMETHYLAMINO)ETHYL)QUINOLINO[3,4-B]QUINOXALIN 6 AMINE; N (2 (MORPHOLINOETHYL)QUINOLINO[3,4-B]QUINOXALIN 6 AMINE; N (2 (PIPERIDIN 1 YL)QUINOLINO[3,4-B]QUINOXALIN 6 AMINE; N (3 (DIMETHYLAMINO)PROPYL)QUINOLINO[3,4-B]QUINOXALIN 6 AMINE; N (4 (DIMETHYLAMINO)BUTYL)QUINOLINO[3,4-B]QUINOXALIN 6 AMINE; N (5 (N BENZYL N METHYLAMINO)PENTYL)QUINOLINO[3,4-B]QUINOXALIN 6 AMINE; N, N DIETHYL 3 (QUINOLINO[3,4-B]QUINOXALIN 6 YLOXY)ETHAMINE; N, N DIMETHYL 2 (QUINOLINO[3,4-B]QUINOXALIN 6 YLOXY)ETHANAMINE; N, N DIMETHYL 2 (QUINOLINO[3,4-B]QUINOXALIN 6 YLTHIO)ETHANAMINE; N, N DIMETHYL 3 (QUINOLINO[3,4-B]QUINOXALIN 6 YLOXY)PROPAN 1 AMINE; NOVOBIOCIN; QUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE IV; GYRASE INHIBITOR; TUMOR ANTIGEN;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CYTOTOXICITY; DNA BINDING; DNA DENATURATION; DNA HELIX; DNA SEQUENCE; DNA STRUCTURE; DRUG BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MCF 7 CELL LINE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CHEMISTRY TECHNIQUES, SYNTHETIC; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; G-QUADRUPLEXES; HELA CELLS; HUMANS; QUINOLINES; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS;

EID: 84982843814     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.07.063     Document Type: Article

References (42)

1. [1] Afzal, O., Kumar, S., Haider, M.R., Ali, M.R., Kumar, R., Jaggi, M., Bawa, S., A review on anticancer potential of bioactive heterocycle quinoline. Eur. J. Med. Chem. 97 (2015), 871–910.
2. [2] Ali, A., Bhattacharya, S., DNA binders in clinical trials and chemotherapy. Bioorg. Med. Chem. 22 (2014), 4506–4521.
3. [3] Ishida, K., Asao, T., Self-association and unique DNA binding properties of the anti-cancer agent TAS-103, a dual inhibitor of topoisomerases I and II. Biochim. Biophys. Acta 1587 (2002), 155–163.
4. [4] Torigoe, T., Izumi, H., Wakasugi, T., Niina, I., Igarashi, T., Yoshida, T., Shibuya, I., Chijiiwa, K., Matsuo, K., Itoh, H., Kohno, K., DNA topoisomerase II poison TAS-103 transactivates GC-box dependent transcription via acetylation of Sp1. J. Biol. Chem. 280 (2005), 1179–1185.
5. [5] Yoshida, M., Kabe, Y., Wada, T., Asai, A., Handa, H., A new mechanism of TAS-103 action discovered by target screening with drug immobilized affinity beads. Mol. Pharmacol. 73 (2008), 987–994.
6. [6] Fujimoto, S., Promising antitumor activity of a novel quinoline derivative, TAS-103, against fresh clinical specimens of eight types of tumors measured by flow cytometric DNA analysis. Biol. Pharm. Bull. 30 (2007), 1923–1929.
7. [7] Luniewski, W., Wietrzyk, J., Godlewska, J., Switalska, M., Piskozu, M., Peczynska-Czoch, W., Kaczmarek, L., New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors. Bioorg. Med. Chem. Lett. 22 (2012), 6103–6107.
8. [8] Godlewska, J., Luniewski, W., Zagrodzki, B., Kaczmarek, L., Bielawska-Pohl, A., Dus, D., Wietrzyk, J., Opolski, A., Siwko, M., Jaromin, A., Jakubiak, A., Kozubek, A., Peczyñska-Czoch, W., Biological evaluation of ω-(dialkylamino)alkyl derivatives of 6H-indolo[2,3-b]quinoline - novel cytotoxic DNA topoisomerase II inhibitors. Anticancer Res. 25 (2005), 2857–2868.
9. [9] Ohnmacht, S.A., Neidle, S., Small-molecule quadruplex-targeted drug discovery. Bioorg. Med. Chem. Lett. 24 (2014), 2602–2612.
10. [10] Zambre, V.P., Giridhar, R., Yadav, M.R., Pharmacophore modeling and 3D-QSAR (CoMSIA) studies for structural requirements of some triazine derivatives as G-quadruplex binders for telomerase inhibition. Med. Chem. Res. 22 (2013), 4685–4699.
11. [11] Bidzinska, J., Cimino-Reale, G., Zaffaroni, N., Folini, M., G-quadruplex structures in the human genome as novel therapeutic targets. Molecules 18 (2013), 12368–12395.
12. [12] Zhang, S., Wu, Y., Zhang, W., G-quadruplex structures and their interaction diversity with ligands. ChemMedChem 9 (2014), 899–911.
13. [13] Drygin, D., Siddiqui-Jain, A., O'Brien, S., Schwaebe, M., Lin, A., Bliesath, J., Ho, C.B., Proffitt, C., Trent, K., Whitten, J.P., Lim, J.K., Von Hoff, D., Anderes, K., Rice, W.G., Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 69 (2009), 7653–7661.
14. [14] Read, M., Harrison, R.J., Romagnoli, B., Tanious, F.A., Gowan, S.H., Reszka, A.P., Wilson, W.D., Kelland, L.R., Neidle, S., Structure-based design of selective and potent G-quadruplex-mediated telomerase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 98 (2001), 4844–4849.
15. [15] Burger, A.M., Dai, F., Schultes, C.M., Reszka, A.P., Moore, M.J., Double, J.A., Neidle, S., The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 65 (2005), 1489–1496.
16. [16] Martins, C., Gunaratnam, M., Stuart, J., Makwana, V., Greciano, O., Reszka, A.P., Kelland, L.R., Neidle, S., Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents. Bioorg. Med. Chem. Lett. 17 (2007), 2293–2298.
17. [17] Ou, T.M., Lin, J., Lu, Y.J., Hou, J.Q., Tan, J.H., Chen, S.H., Li, Z., Li, Y.P., Li, D., Gu, L.Q., Huang, Z.S., Inhibition of cell proliferation by quindoline derivative (SYUIQ-05) through its preferential interaction with c-myc promoter G-quadruplex. J. Med. Chem. 54 (2011), 5671–5679.
18. [18] Shibinskay, M.O., Lyakhov, S.A., Mazepa, A.V., Andronati, S.A., Turov, A.V., Zholobak, N.M., Spivak, N.Y., Synthesis, cytotoxicity, antiviral activity and interferon inducing ability of 6-(2-aminoethyl)-6H-indolo[2,3-b]quinoxalines. Eur. J. Med. Chem. 45 (2010), 1237–1243.
19. [19] Harmenberg, J., Wahren, B., Bergman, J., Åkerfeldt, S., Lundblad, L., Antiherpesvirus activity and mechanism of action of indolo-[2,3-b]quinoxaline and analogs. Antimicrob. Agents Chemother. 32 (1988), 1720–1724.
20. [20] Harmenberg, J., Åkesson-Johansson, A., Gräslund, A., Malmfors, T., Bergman, J., Wahren, B., Åkerfeldt, S., Lundblad, L., Cox, S., The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-[2,3-b]quinoxaline. Antivir. Res. 15 (1991), 193–204.
21. [21] U. Björklund, R. Engqvist, I. Kihlström, B. Gerdin, J. Bergman, Alkyl Substituted Indoloquinoxalines, Patent WO 2005/123741.
22. [22] De Sarro, G., Carotti, A., Campagna, F., McKernan, R., Rizzo, M., Falconi, U., Palluotto, F., Giusti, P., Rettore, C., De Sarro, A., Benzodiazepine receptor affinities, behavioral, and anticonvulsant activity of 2-aryl-2,5dihydropyridazino[4,3-b]indol-3(3H)-ones in mice. Pharmacol. Biochem. Behav. 65 (2000), 475–487.
23. [23] Campagna, F., Palluotto, F., Carotti, A., Casini, G., Genchi, G., Synthesis and structure-activity relationships at the central benzodiazepine receptor of pyridazino[4,3-b]indoles and indeno[1,2-c]pyridazines. Bioorg. Med. Chem. 7 (1999), 1533–1538.
24. [24] Palluotto, F., Carotti, A., Casini, G., Genchi, G., Rizzo, M., De Sarro, G.B., Structure-activity relationships of 2,5-dihydropyridazino[4,3-b]indol-3(3H)-ones at the benzodiazepine receptor. Bioorg. Med. Chem. 4 (1996), 2091–2104.
25. [25] G.A. Pagani, L. Beverina, M. Sassi, M. M. Salamone, C. M. Mari, R. Ruffo, Organic electrochromic materials having high transparency and high contrast in the visible range, Patent WO2013/038243.
26. [26] Ziegler, E., Salvador, R., Kappe, T., Synthesen von Heterocyclen, 41. Mitt.: Über cyclische Dichlormalonyl-Verbindungen. Monatsh. Chem. 93 (1962), 1376–1381.
27. [27] Fournier, C., Decombe, J., Chemistry of homophthalimide and 4-hydroxycarbostyril. Bull. Soc. Chim. Fr. 9 (1967), 3367–3371.
28. [28] Kappe, T., Reichel-Lender, E., Zeigler, E., Synthesen von Heterocyclen, 125 Mitt.: Über kondensierte Chinoxalinderivate. Monatsh. Chem. 100 (1969), 458–461.
29. [29] Blicke, F.F., Biel, J.H., Aminolysis products of 1-chloro-2-hydroxy-3-butene, 1-hydroxy-2-chloro-3-butene and 1,2-epoxy-3-butene. J. Am. Chem. Soc. 79 (1957), 5508–5512.
30. [30] Littmann, E.R., Marvel, C.S., Cyclic quaternary ammonium salts from halogenated aliphatic tertiary amines. J. Am. Chem. Soc. 52 (1930), 287–294.
31. [31] Kappe, T., Lendee, E., Ziegler, E., Synthesen von Heterocyclen, 118 Mitt.: Uber Reaktionem mit heterocyclischen Aminalen. Monatsh. Chem. 99 (1968), 2157–2166.
32. [32] Wang, J.C., DNA topoisomerases. Annu. Rev. Biochem. 65 (1996), 635–692.
33. [33] Christensen, M.O., Larsen, M.K., Barthelmes, H.U., Hock, R., Andersen, C.L., Kjeldsen, E., Knudsen, B.R., Westergaard, O., Boege, F., Mielke, C., Dynamics of human DNA topoisomerases IIalpha and IIbeta in living cells. J. Cell. Biol. 157 (2002), 31–44.
34. [34] Pommier, Y., Leo, E., Zhang, H., Marchand, C., DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17 (2010), 421–433.
35. [35] Vos, S.M., Lee, I., Berger, J.M., Distinct regions of the Escherichia coli ParC C-terminal domain are required for substrate discrimination by topoisomerase IV. J. Mol. Biol. 425 (2013), 3029–3045.
36. [36] Dai, J., Carver, M., Yang, D., Polymorphism of human telomeric quadruplex structures. Biochimie 90 (2008), 1172–1183.
37. [37] Balasubramanian, S., Hurley, L.H., Neidle, S., Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?. Nat. Rev. Drug Discov. 10 (2011), 261–275.
38. [38] Tran, P.L., Largy, E., Hamon, F., Teulade-Fichou, M.P., Mergny, J.L., Fluorescence intercalator displacement assay for screening G4 ligands towards a variety of G-quadruplex structures. Biochimie 93 (2011), 1288–1296.
39. [39] Gianoncelli, A., Basili, S., Scalabrin, M., Sosic, A., Moro, S., Zagotto, G., Palumbo, M., Gresh, N., Gatto, B., Rational design, synthesis, and DNA binding properties of novel sequence-selective peptidyl congeners of ametantrone. ChemMedChem 5 (2010), 1080–1091.
40. [40] Lavrado, J., Borralho, P.M., Ohnmacht, S.A., Castro, R.E., Rodrigues, C.M.P., Moreira, R., dos Santos, D.J.V.A., Neidle, S., Paulo, A., Synthesis, G-quadruplex stabilisation, docking studies, and effect on cancer cells of indolo[3,2-b]quinolines with one, two, or three basic side chains. ChemMedChem 8 (2013), 1648–1661.
41. [41] Contreras, J.M., Rival, Y.M., Chayer, S., Bourguignon, J.J., Wermuth, C.G., Aminopyridazines as acetylcholinesterase inhibitors. J. Med. Chem. 42 (1999), 730–741.
42. [42] Osheroff, N., Bjornsti, M.A., (eds.) DNA Topoisomerase Protocols. Part II: Enzymology and Drugs, Methods in Molecular Biology, vol. 95, 2001, Humana Press Inc., Totowa, New Jersey.